Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

7-ethyl-10-hydroxycamptothecin glucuronide

Known as: SN-38 glucuronide 
 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

CamptothecinGlucuronides
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2009
Highly Cited
2009
Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics.
PURPOSE We aim to identify genetic variation, in addition to the UGT1A1*28 polymorphism, that can explain the variability in… Expand
  • figure 1
  • table 1
  • table 1
  • table 2
  • table 2
Is this relevant?
2008
2008
Pharmacogenetic pathway analysis of irinotecan.
Irinotecan, a chemotherapeutic agent against various solid tumors, is a prodrug requiring activation to SN-38. Irinotecan's… Expand
Is this relevant?
2008
2008
Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma.
The coadministration of protease inhibitors with anticancer drugs in the management of human immunodeficiency virus-related… Expand
Is this relevant?
2004
2004
Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study.
This study was conducted to determine the maximum tolerated dose and dose-limiting toxicity of irinotecan (CPT-11) administered… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • table 4
Is this relevant?
Highly Cited
2002
Highly Cited
2002
UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity
The metabolism of irinotecan (CPT-11) involves sequential activation to SN-38 and detoxification to the pharmacologically… Expand
  • figure 1
  • table 1
  • figure 2
Is this relevant?
Highly Cited
2002
Highly Cited
2002
The potential for an interaction between MRP2 (ABCC2) and various therapeutic agents: probenecid as a candidate inhibitor of the biliary excretion of irinotecan metabolites.
Irinotecan hydrochloride (CPT-11) is an anticancer agent with unpredictable bouts of diarrhea as a dose-limiting toxic side… Expand
Is this relevant?
2002
2002
Population pharmacokinetic model for irinotecan and two of its metabolites, SN-38 and SN-38 glucuronide.
OBJECTIVE The objective of the study was to develop and validate a population pharmacokinetic model for irinotecan and 2 of its… Expand
Is this relevant?
Highly Cited
1999
Highly Cited
1999
Irinotecan therapy in adults with recurrent or progressive malignant glioma.
PURPOSE To determine the activity, toxicity, and pharmacokinetics of irinotecan (CPT-11, Camptosar; Pharmacia & Upjohn, Kalamazoo… Expand
Is this relevant?
1998
1998
Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors.
PURPOSE In vitro synergy between cisplatin and irinotecan (CPT-11) has been reported. We designed a combination schedule of these… Expand
Is this relevant?
1996
1996
Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and…
PURPOSE A pharmacokinetic study was performed during a phase II clinical trial of irinotecan (CPT-11) to confirm the… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE